Teva Pharma Industries Ltd ADR
$ 35.36
1.58%
07 Aug - close price
- Market Cap 41,204,871,000 USD
- Current Price $ 35.36
- High / Low $ 35.77 / 34.87
- Stock P/E 58.93
- Book Value 6.65
- EPS 0.60
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.10 %
- 52 Week High 37.35
- 52 Week Low 16.26
About
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Analyst Target Price
$41.20
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-29 | 2026-04-29 | 2026-01-28 | 2025-11-05 | 2025-07-30 | 2025-05-07 | 2025-01-29 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-01-31 | 2023-11-08 |
| Reported EPS | 0.64 | 0.53 | 0.96 | 0.75 | 0.66 | 0.52 | 0.71 | 0.69 | 0.61 | 0.48 | 1 | 0.6 |
| Estimated EPS | 0.05 | 0.46 | 0.64 | 0.66 | 0.62 | 0.46 | 0.7 | 0.66 | 0.55 | 0.51 | 0.76 | 0.61 |
| Surprise | 0.59 | 0.07 | 0.32 | 0.09 | 0.04 | 0.06 | 0.01 | 0.03 | 0.06 | -0.03 | 0.24 | -0.01 |
| Surprise Percentage | 1180% | 15.2174% | 50% | 13.6364% | 6.4516% | 13.0435% | 1.4286% | 4.5455% | 10.9091% | -5.8824% | 31.5789% | -1.6393% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.085 | $0.07225 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TEVA
2026-08-09 09:40:46
Teva Pharmaceuticals has requested that a U.S. judge prevent insurer Humana from revealing its Israeli origins to jurors in an upcoming price-fixing trial. The company argues that strong public sentiment regarding the Gaza war could prejudice the proceedings and hinder its ability to receive a fair hearing. This move highlights how geopolitical tensions are affecting legal cases in the United States.
2026-08-09 07:40:46
Empowered Funds LLC significantly increased its stake in Teva Pharmaceutical Industries Ltd. by 1,146.4% in the first quarter, now owning 37,430 shares valued at $1.13 million. Despite a "Moderate Buy" consensus from analysts and a $42.00 average price target, an executive recently sold 61.89% of their shares. Teva reported quarterly revenue of $4.14 billion and trades near its 52-week high, with institutional investors holding 54.05% of its stock.
2026-08-08 18:40:46
Teva Pharmaceutical Industries (TEVA) recently raised its 2026 revenue outlook and confirmed mid-single-digit growth targets for 2027, despite reporting a net loss in its second quarter results. The stock has seen significant momentum over the past year with a 113.69% total shareholder return. Analysts hold a consensus price target of $40.90, framing a valuation debate as the stock is currently seen by some models as undervalued, while others indicate a much larger gap.
2026-08-08 09:10:21
This Yahoo Finance page provides comprehensive information on Teva Pharmaceutical Industries Limited (TEVA), including its current stock price, news headlines, and historical performance data. The stock closed at $35.36, up 1.58% on August 7, and traded slightly down in after-hours. The news section highlights recent events such as Q2 earnings reports, updated revenue guidance, and drug pipeline developments.
2026-08-08 08:10:21
Assenagon Asset Management S.A. significantly increased its stake in Teva Pharmaceutical Industries Ltd. by 128.1% in the second quarter, now holding over 3 million shares valued at approximately $103.5 million. Institutional investors collectively own 54.05% of Teva, and analysts maintain a "Moderate Buy" rating with an average price target of $42. The article also notes an insider sale by EVP Eliyahu Sharon Kalif and details Teva's recent financial performance and current market data.
2026-08-07 21:10:21
Teva Pharmaceutical Industries (TEVA) has raised its 2026 revenue outlook and confirmed mid-single-digit revenue growth targets for 2027, despite reporting a net loss in the second quarter. The stock has seen significant momentum, with a 113.69% return over the last year, leading to a debate among investors and analysts regarding its current valuation. While one narrative suggests it's 14.9% undervalued at $40.90 per share, an alternative DCF model indicates a much higher fair value of $64.78.
